5 documents found, page 1 of 1
Cognitive Disorders in Patients with Chronic Kidney Disease: Approaches to Prev...
Pépin, M; Klimkowicz‐Mrowiec, A; Godefroy, O; Delgado, P; Carriazo, S; Ferreira, AC; Golenia, A; Malyszko, J; Grodzicki, T; Giannakou, K; Paolisso, GBackground: Cognitive impairment is common in patients with chronic kidney disease (CKD), and early intervention may prevent the progression of this condition. Methods: Here, we review interventions for the complications of CKD (anemia, secondary hyperparathyroidism, metabolic acidosis, harmful effects of dialysis, the accumulation of uremic toxins) and for prevention of vascular events, interventions that may ...
Anemia and Iron Deficiency Diagnosis, Management and Treatment in Chronic Kidne...
Ferreira, A; Farinha, A; Macedo, A; Robalo Nunes, A; Lopes, J; Branco, P; Ponce, P; Neto, RBackground: Anemia is a common complication of Chronic Kidney Disease (CKD), in which iron deficiency’s (ID) role is frequently underrated. In CKD, anemia has been associated with higher morbidity and lower quality of life. Nonetheless, reported treatment rates of anemia in CKD are low and guidelines’ variability and/or absence for its management and treatment may be preventing patients from receiving optimal t...
O sono na doença renal crónica
Figueiredo-Cardoso, M; Farinha, A
In vivo evaluation of photoprotective activity of solid lipid nanoparticles for...
Toscano, C; Farinha, A; Pinto, PC; Magro, JM; Rei, F; Almeida, AJ; Rodrigues, LM
Determination of clonixin in plasma and urine by reversed-phase high-performanc...
Bica, A; Farinha, A; Blume, H; Barbosa, CMA reversed-phase high-performance liquid chromatographic method that enables the determination of clonixin in human plasma and urine samples is described. Recovery of the drug was over 87.6 and 80.7% for plasma and urine, respectively. The limit of quantitation of the method was established as 10 ng/ml in plasma and 20 ng/ml in urine samples, with RSDs of less than 11.1%. The applicability of the method was fur...